Welcome to our dedicated page for OptimizeRx Corporation news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on OptimizeRx Corporation stock.
OptimizeRx Corporation (NASDAQ: OPRX) is a leading provider in the healthcare technology sector, offering digital health messaging solutions that enhance communication between pharmaceutical companies, healthcare providers, and patients. OptimizeRx specializes in the integration of electronic health records (EHR) to distribute financial assistance, educational materials, and clinical information directly at the point of care.
The company leverages its proprietary SampleMD and eCoupon technologies to expand the distribution of patient savings and support materials within the e-prescribing workflows of over 300,000 healthcare providers. These platforms enable healthcare providers to deliver real-time financial assistance and support to patients, thereby improving medication adherence and affordability.
OptimizeRx offers a range of products, including Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement. These solutions aim to help patients start and stay on their prescribed treatments while providing pharmaceutical companies with efficient ways to increase brand awareness and adherence.
Recently, OptimizeRx has undergone significant leadership changes. Gus Halas retired as Chairperson of the Board, succeeded by Lynn O’Connor Vos, a seasoned executive with extensive experience in healthcare IT and life sciences. Additionally, Catherine M. Klema was appointed to the Board, bringing her expertise in strategy, finance, and governance.
Financially, OptimizeRx is in a robust position. The company's revenue for FY2023 is estimated to exceed $68-$70 million, with adjusted EBITDA ranging between $3-$4 million. For 2024, the company anticipates revenue of at least $100 million due to a revised gross-to-net accounting treatment for certain revenue streams from its recent acquisition of Medicx Health.
The mission of OptimizeRx is to empower the healthcare community through innovative, tech-enabled communication solutions that improve patient care. By connecting over 60% of U.S. healthcare providers and millions of patients through its digital point-of-care network, OptimizeRx continues to deliver significant value to patients, healthcare professionals, and investors.
For more information, visit www.optimizerx.com
OptimizeRx Corp. (Nasdaq: OPRX) will hold a conference call on August 4, 2021, at 4:30 p.m. Eastern time to discuss its Q2 2021 results, ending June 30, 2021. Financial results will be issued ahead of the call, which will be followed by a Q&A session. The company provides digital health solutions, connecting healthcare providers and patients through its platform. This platform enhances medication adherence and creates new engagement opportunities for life science companies during the patient journey.
OptimizeRx has signed an agreement with a leading pharmaceutical company to enhance a patient affordability initiative.
The OptimizeRx platform utilizes real-world evidence (RWE) to assist physicians in managing Medicare patients’ treatment plans, preventing lapses due to coverage gaps.
This initiative aims to support patients in staying on their prescribed treatment without unexpected out-of-pocket costs, thus improving health outcomes.
OptimizeRx connects healthcare providers and patients, enhancing treatment adherence through its AI-driven platform.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, is strengthening its enterprise solutions in oncology, cardiology, and immunology. Customer engagement in these areas has surged by 600% in two years, now projected to represent at least 50% of future revenue. The company is enhancing partnerships and expanding its omni-channel platform, reaching over 50% of U.S. oncologists. Notably, specialty medicines account for 53% of spending, reflecting significant market growth.
OptimizeRx Corp. (Nasdaq: OPRX) announced that CEO Will Febbo will participate in a fireside chat at the William Blair 41st Annual Growth Stock Conference. The event will take place virtually on June 2, 2021, from 9:20-9:50 AM CT (10:20-10:50 AM ET). A live webcast and replay will be available on the company's investor relations website. OptimizeRx offers digital health solutions connecting healthcare providers and patients, aiming to enhance medication affordability and adherence.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, will participate in the RBC Capital Markets Global Healthcare Virtual Conference. CEO Will Febbo is scheduled for a fireside chat on May 19, 2021, at 8:00 a.m. ET. The presentation can be accessed live on the company's investor website. OptimizeRx offers a digital platform that connects healthcare providers and patients, enhancing medication affordability and adherence through innovative communication solutions. For updates, follow OptimizeRx on social media or visit their website.
OptimizeRx Corp. (Nasdaq: OPRX) reported a 48% revenue increase in Q1 2021, reaching $11.2 million compared to $7.6 million year-over-year. Gross profit rose 41% to $6.1 million, though GAAP net loss was $0.6 million or $(0.04) per share.
The company achieved cash flow positivity from operations at $1.7 million, bolstered by a successful equity offering raising $70.7 million. 33 enterprise contracts worth $25 million in annual value were secured. Cash and cash equivalents soared to $82.3 million by March 31, 2021.
OptimizeRx Corporation (Nasdaq: OPRX) will hold a conference call on May 6, 2021, at 4:30 p.m. Eastern to discuss its first quarter financial results for the period ending March 31, 2021. A press release with the financial results will precede the call, where management will address questions afterward. Interested parties can access the call via a toll-free number or the web. The company is recognized for its digital health solutions, connecting a significant network of healthcare providers and patients to enhance medication adherence.
OptimizeRx Corp. (Nasdaq: OPRX) has expanded its digital health platform through new health information technology partnerships, significantly increasing its reach to over 50% of oncologists in the U.S. This initiative is aimed at enhancing connections between life science companies and healthcare providers. The partnerships diversify the channel mix available for customer engagement, which is crucial for addressing the challenges of affordability and access in oncology. The new collaborations strengthen the company’s position in delivering personalized treatment resources at the point-of-care.
FAQ
What is the current stock price of OptimizeRx Corporation (OPRX)?
What is the market cap of OptimizeRx Corporation (OPRX)?
What does OptimizeRx Corporation do?
What are the main products offered by OptimizeRx?
How does OptimizeRx help patients?
Who is the current Chairperson of OptimizeRx?
What recent changes have occurred in OptimizeRx's leadership?
What are OptimizeRx's financial expectations for 2024?
How widely is OptimizeRx's technology adopted?
What is SampleMD?
Where can I find more information about OptimizeRx?
What is the mission of OptimizeRx?
